Researchers at the University of Pittsburgh have identified a trigger of high-grade serous ovarian cancer: a subset of progenitor cells that reside in fallopian tube supportive tissue, or stroma.
Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science Advances, could improve treatment approaches for this type of cancer.
